CIBC Bancorp USA Inc. Buys New Position in Axon Enterprise, Inc $AXON

Key Points

• CIBC Bancorp USA opened a new position in Axon, acquiring 13,542 shares worth about $9.72 million in the 3rd quarter, and institutional investors now own roughly 79.08% of the company.
• Axon beat its February quarter expectations with EPS $2.15 vs. $1.60 and revenue of $796.72 million (up 38.5% YoY), though the stock carries a premium valuation (market cap ~$39.9B, P/E ~326).
• Insiders sold about 23,855 shares (~$13.3M) last quarter (insiders own 4.40%), while Wall Street maintains a consensus "Moderate Buy" rating with a $762.93 average target amid several recent price‑target cuts.

CIBC Bancorp USA Inc. acquired a new position in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 13,542 shares of the biotechnology company's stock, valued at approximately $9,718,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. NEOS Investment Management LLC lifted its holdings in shares of Axon Enterprise by 82.7% in the 3rd quarter. NEOS Investment Management LLC now owns 25,369 shares of the biotechnology company's stock worth $18,206,000 after acquiring an additional 11,482 shares during the last quarter. Vanguard Group Inc. lifted its stake in Axon Enterprise by 4.2% in the third quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company's stock worth $6,684,217,000 after acquiring an additional 376,904 shares during the period. Sumitomo Mitsui Trust Group Inc. raised its holdings in Axon Enterprise by 3.3% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 184,423 shares of the biotechnology company's stock worth $132,349,000 after purchasing an additional 5,953 shares in the last quarter. BIT Capital GmbH raised its holdings in Axon Enterprise by 75.6% in the 3rd quarter. BIT Capital GmbH now owns 3,535 shares of the biotechnology company's stock worth $2,537,000 after purchasing an additional 1,522 shares in the last quarter. Finally, Legal & General Group Plc lifted its position in shares of Axon Enterprise by 3.1% in the 3rd quarter. Legal & General Group Plc now owns 421,114 shares of the biotechnology company's stock worth $302,208,000 after purchasing an additional 12,736 shares during the period. Institutional investors own 79.08% of the company's stock.

Axon Enterprise Price Performance

Shares of AXON stock opened at $496.12 on Friday. The company has a market capitalization of $39.89 billion, a PE ratio of 326.39, a price-to-earnings-growth ratio of 10.72 and a beta of 1.46. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.53 and a quick ratio of 2.29. Axon Enterprise, Inc has a 12 month low of $396.41 and a 12 month high of $885.91. The firm's 50-day moving average is $519.47 and its two-hundred day moving average is $601.32.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share for the quarter, beating analysts' consensus estimates of $1.60 by $0.55. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The business had revenue of $796.72 million for the quarter, compared to analyst estimates of $755.29 million. During the same period last year, the business earned $2.08 EPS. The company's revenue was up 38.5% on a year-over-year basis. Analysts predict that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Jeri Williams sold 157 shares of the business's stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $490.00, for a total value of $76,930.00. Following the transaction, the director owned 1,159 shares in the company, valued at $567,910. The trade was a 11.93% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Isaiah Fields sold 2,000 shares of the company's stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $535.01, for a total value of $1,070,020.00. Following the sale, the insider owned 55,588 shares of the company's stock, valued at $29,740,135.88. This trade represents a 3.47% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 23,855 shares of company stock valued at $13,299,928 in the last quarter. Corporate insiders own 4.40% of the company's stock.

Key Stories Impacting Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Strong Software & Services momentum supports a higher-margin recurring revenue outlook—analyst write-ups highlight ~38% revenue growth and continued subscription expansion, which underpins long-term upside. Read More.
• Positive Sentiment: Earnings beat: Axon’s Feb. quarter topped estimates on EPS and revenue (revenue up ~38.5% YoY), reinforcing the growth narrative that many investors cite when valuing the stock. Read More.
• Positive Sentiment: Municipal procurement continues to drive hardware + software adoption—local grants (e.g., Decatur, IL) are cited as examples of steady demand for public-safety tech. Read More.
• Positive Sentiment: Institutional/coverage interest (features mentioning funds and “trending” status) can attract flows and boost liquidity, supporting the stock over time. Read More.
• Neutral Sentiment: Aggregator/“trending” articles raise awareness but are not direct fundamental catalysts; useful for retail/institutional interest but don’t change cash flows immediately. Read More.
• Neutral Sentiment: Short-interest data being reported as “0 shares” with NaN changes reads like a reporting error—treat as noise until exchanges/brokers clarify; not an actionable signal now.
• Negative Sentiment: Insider selling: Director Erika Nardini sold 198 shares (~$506.58 avg) and Director Jeri Williams sold 157 shares (~$490 avg) in mid‑March; while small in absolute dollars, these filings can dent sentiment. Read More. Read More.
• Negative Sentiment: Near-term skepticism: critical pieces noting a multi‑day losing streak and a sizable short-term market‑cap decline are amplifying caution and likely contributing to today’s pullback. Read More.

Wall Street Analysts Forecast Growth

AXON has been the topic of a number of recent research reports. Morgan Stanley reduced their target price on shares of Axon Enterprise from $713.00 to $675.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 25th. Citigroup reaffirmed a "buy" rating on shares of Axon Enterprise in a research note on Wednesday, February 25th. UBS Group reduced their price target on shares of Axon Enterprise from $610.00 to $570.00 and set a "neutral" rating on the stock in a report on Wednesday, February 25th. Northcoast Research upgraded Axon Enterprise from a "neutral" rating to a "buy" rating and set a $742.00 target price for the company in a report on Tuesday, January 6th. Finally, Needham & Company LLC cut their price target on shares of Axon Enterprise from $870.00 to $600.00 and set a "buy" rating on the stock in a report on Friday, February 20th. Sixteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat, Axon Enterprise presently has a consensus rating of "Moderate Buy" and a consensus target price of $762.93.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company's hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.